NCT01505699

Brief Summary

RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer. PURPOSE: This research study is studying biomarkers in samples from patients with acute lymphoblastic leukemia enrolled on ECOG-2993 clinical trial.

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
186

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Jan 2012

Shorter than P25 for all trials

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

January 4, 2012

Completed
2 days until next milestone

First Posted

Study publicly available on registry

January 6, 2012

Completed
Same day until next milestone

Study Start

First participant enrolled

January 6, 2012

Completed
1 month until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 6, 2012

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

February 6, 2012

Completed
Last Updated

May 17, 2017

Status Verified

May 1, 2017

Enrollment Period

1 month

First QC Date

January 4, 2012

Last Update Submit

May 16, 2017

Conditions

Leukemia

Keywords

adult acute lymphoblastic leukemia in remissionB-cell adult acute lymphoblastic leukemia

Outcome Measures

Primary Outcomes (3)

  • Comprehensive view of microRNA expression by cytogenetic subgroup

    1 year

  • MicroRNA expression in relation to clinical outcome

    1 year

  • Differential microRNA expression between normal B-cells and progenitors compared to B-ALL

    1 year

Interventions

RNA analysisGENETIC
cytogenetic analysisGENETIC
microarray analysisGENETIC
laboratory biomarker analysisOTHER

Eligibility Criteria

Age15 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Samples from patients enrolled on E2993 who provided samples for research

DISEASE CHARACTERISTICS: * Samples from patients enrolled on ECOG-2993 * Samples from patients with recurrent cytogenetic abnormalities other than BCR-ABL, including MLL/AF4, E2A/PBX1, and TEL/AML1 PATIENT CHARACTERISTICS: * Not specified PRIOR CONCURRENT THERAPY: * Not specified

Contact the study team to discuss eligibility requirements. They can help determine if this study is right for you.

Sponsors & Collaborators

MeSH Terms

Conditions

Leukemia

Interventions

Cytogenetic AnalysisMicroarray Analysis

Condition Hierarchy (Ancestors)

Neoplasms by Histologic TypeNeoplasmsHematologic DiseasesHemic and Lymphatic Diseases

Intervention Hierarchy (Ancestors)

Cytological TechniquesClinical Laboratory TechniquesDiagnostic Techniques and ProceduresDiagnosisInvestigative TechniquesGenetic TechniquesMicrochip Analytical Procedures

Study Officials

  • Hans-Guido Wendel, MD

    Memorial Sloan Kettering Cancer Center

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
RETROSPECTIVE
Sponsor Type
NETWORK
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 4, 2012

First Posted

January 6, 2012

Study Start

January 6, 2012

Primary Completion

February 6, 2012

Study Completion

February 6, 2012

Last Updated

May 17, 2017

Record last verified: 2017-05